320 related articles for article (PubMed ID: 34020073)
1. In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy.
Stracquadanio S; Torti E; Longshaw C; Henriksen AS; Stefani S
J Glob Antimicrob Resist; 2021 Jun; 25():390-398. PubMed ID: 34020073
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
3.
Naas T; Lina G; Santerre Henriksen A; Longshaw C; Jehl F
JAC Antimicrob Resist; 2021 Jun; 3(2):dlab081. PubMed ID: 34223140
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.
Cercenado E; Cardenoso L; Penin R; Longshaw C; Henriksen AS; Pascual A
J Glob Antimicrob Resist; 2021 Sep; 26():292-300. PubMed ID: 34274538
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018.
Gant V; Hussain A; Bain M; Longshaw C; Henriksen AS
J Glob Antimicrob Resist; 2021 Dec; 27():1-11. PubMed ID: 34329792
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany.
Thelen P; Henriksen AS; Longshaw C; Yamano Y; Caldwell B; Hamprecht A
J Glob Antimicrob Resist; 2022 Mar; 28():12-17. PubMed ID: 34920174
[TBL] [Abstract][Full Text] [Related]
7.
Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0199021. PubMed ID: 34807757
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
10. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
11.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
12.
Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
[TBL] [Abstract][Full Text] [Related]
13.
Wise MG; Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
Microb Drug Resist; 2023 Aug; 29(8):360-370. PubMed ID: 37253158
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
[TBL] [Abstract][Full Text] [Related]
16. Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes.
Bianco G; Boattini M; Comini S; Iannaccone M; Casale R; Allizond V; Barbui AM; Banche G; Cavallo R; Costa C
J Chemother; 2022 Sep; 34(5):302-310. PubMed ID: 35098907
[TBL] [Abstract][Full Text] [Related]
17. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
Sader HS; Carvalhaes CG; Duncan LR; Flamm RK; Shortridge D
J Antimicrob Chemother; 2020 Oct; 75(10):2907-2913. PubMed ID: 32653914
[TBL] [Abstract][Full Text] [Related]
19.
Borde K; Kareem MA; Sharma RM; Dass SM; Ravi V; Mathai D
Microbiol Spectr; 2023 Sep; 11(5):e0084723. PubMed ID: 37737637
[TBL] [Abstract][Full Text] [Related]
20. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P
Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
